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Inherent in the approach to phase-appropriate development is the need for multiple process development 
cycles.  A major advantage in this approach is that resources can be minimized in the development of early 
phase programs, which can be then put toward later phase programs that have a higher probability for 
commercial success.  In this paradigm, it is the goal for early development to quickly transition from research to 
the clinic with clinical timelines being the main development constraint.  Subsequently, the goal of late stage 
development is the generation of a commercially viable process with matching early-phase product quality being 
the main development constraint.  The length of clinical timelines can have additional impact on how 
development cycles are assessed and initiated where short timelines pressure early phase processes to deliver 
commercial ready processes and long timelines push late phase processes to higher titers.  During late-stage 
development, media components are often screened and balanced that can have a positive impact to process 
yield and/or robustness.  Here, we show the results of a novel epigenetic inhibitor that improved process yield 
by approximately two-fold while also having a positive impact to process robustness.  An omics approach was 
then applied to determine the mechanism for this improvement.  Rationale media design was then applied to 
determine the optimal concentration and delivery method for optimizing the fed-batch process.  Finally, we 
explore the molecules impact on product quality and how a robust end-to-end protein platform can mitigate 
potential product quality comparability risks between development cycles. 
 
 
 
